Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy

Archives of Otolaryngology - Head and Neck Surgery

Volumn 133, Issue 5, 2007, Pages 435-440

  Tan, Ann ^a   Adelstein, David J ^a   Rybicki, Lisa A ^b   Saxton, Jerrold P ^b   Esclamado, Ramon M ^b   Wood, Benjamin G ^b   Lorenz, Robert R ^b   Strome, Marshall ^b   Carroll, Marjorie A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CERVICAL LYMPH NODE; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TERTIARY HEALTH CARE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; NECK DISSECTION; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 34249031529     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.133.5.435     Document Type: Review

References (44)

1. Peters LJ, Weber RS, Morrison WH, Byers RM, Garden AS, Goepfert H. Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. Head Neck. 1996;18:552-559.
2. Pfister DG, Ang K, Brockstein B, et al; National Comprehensive Cancer Network. NCCN practice guidelines for head and neck cancers. Oncology (Williston Park). 2000;14(11A):163-194.
3. Armstrong J, Pfister D, Strong E, et al. The management of the clinically positive neck as part of a larynx preservation approach. Int J Radiat Oncol Biol Phys. 1993; 26:759-765.
4. Garden AS, Glisson BS, Ang KK, et al. Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of head and neck: toxicities and responses. J Clin Oncol. 1999;17:2390-2395.
5. Corry J, Rischin D, Smith JG, et al. Radiation with concurrent late chemotherapy intensification ("chemoboost") for locally advanced head and neck cancer. Radiother Oncol. 2000;54:123-127.
6. Johnson CR, Silverman LN, Clay LB, Schmidt-Ullrich R. Radiotherapeutic management of bulky cervical lymphadenopathy in squamous cell carcinoma of the head and neck: is postradiotherapy neck dissection necessary? Radiat Oncol Investig. 1998;6:52-57.
7. Strasser MD, Gleich LL, Miller MA, Saavedra HI, Gluckman JL. Management implication of evaluating the N2 and N3 neck after organ preservation therapy. Laryngoscope. 1999;109:1776-1780.
8. Roy S, Tibesar RJ, Daly KD, et al. Role of planned neck dissection for advanced metastatic disease in tongue base or tonsil squamous cell carcinoma treated with radiotherapy. Head Neck. 2002;24:474-481.
9. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000;126:950-956.
10. Wanebo H, Chougule P, Ready N, et al. Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of head and neck (stage III and IV). Ann Surg Oncol. 2001;8:644-650.
11. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck. 2003;25:791-798.
12. Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004;26:447-455.
13. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2004;58:1418-1423.
14. Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive nodes. Head Neck. 1999;21:591-594.
15. Bernier J, Bataini JP. Regional outcome in oropharyngeal and pharyngolaryngeal cancer treated with high dose per fraction radiotherapy: analysis of neck disease response in 1646 cases. Radiother Oncol. 1986;6:87-103.
16. Corey JP, Caldarelli DD, Hutchinson JC Jr, et al. Surgical complications in patients with head and neck cancer receiving chemotherapy. Arch Otolaryngol Head Neck Surg. 1986;112:437-439.
17. Lavertu P, Bonafede JP, Adelstein DJ, et al. Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998;124:401-406.
18. Newman JP, Fee WE, Terris DJ, Fee WE Jr, Goode RL, Goffinet DR. Surgical morbidity of neck dissection after chemoradiotherapy in advanced head and neck cancer. Ann Otol Rhinol Laryngol. 1997;106:117-122.
19. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
20. Di Chiro G, DeLa Paz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
21. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
22. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(suppl): 1S-93S.
23. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotic therapy with FDG PET. Eur J Nucl Med Mol Imaging. 2004;31:1471-1478.
24. Khan N, Oriuch N, Yoshizaki A, Kanuma T, Higuchi T, Endo K. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med. 2005;19:137-145.
25. Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S. F-18-flurodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg. 2005;9:22-28.
26. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005;27:175-181.
27. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31:590-595.
28. Kovács AF, Dobert N, Gaa J, Menzel C, Bitter K. Positron emission tomography in combination with sentinel node biopsy reduces the rate of elective neck dissections in the treatment of oral and oropharyngeal cancer. J Clin Oncol. 2004; 22:3973-3980.
29. Brkovich VS, Miller FR, Karnad AB, Hussey DH, McGuff HS, Otto RA. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope. 2006;116:855-858.
30. Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645-650.
31. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507.
32. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodexoyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
33. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med. 1996;37:441-446.
34. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355-1359.
35. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942-946.
36. Rogers JW, Greven KM, McGuirt WF, et al. Can post-RT neck dissection be omitted for patients with head and neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys. 2004;58:694-697.
37. Yao M, Buatti JM, Dornfield KJ, et al. Can post-RT FDG PET accurately predict the pathologic status in neck dissection after radiation for locally advanced head and neck cancer? in regard to Rogers et al. (Int J Radiat Oncol Biol Phys 2004; 58:694-697) [letter]. Int J Radiat Oncol Biol Phys. 2005;61:306-307.
38. 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890-896.
39. Chen AY, Vilaseca I, Hudgins P, Schuster D, Halkar R. PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer? Head Neck. 2006;28:487-495.
40. Wensing BM, Vogel WV, Marres HA, et al. FDG-PET in the clinically negative neck in oral squamous cell carcinoma [published correction appears in Laryngoscope. 2006;116(pt 1):1302]. Laryngoscope. 2006;116:809-813.
41. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastases from head and neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991-999.
42. Andrade RS, Heron DE, Degirmenci B, et al. Post-treatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315-1322.
43. Chen YK, Su CT, Ding HJ, et al. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res. 2006;26(2B):1471-1477.
44. Zimmer LA, Branstetter BF, Nayak JV, Johnson JT. Currentuseof 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115:2029-2034.